August 3, 2018 – By Jacqueline McKee
Bvf Inc decreased Chemocentryx Inc (CCXI) stake by 5.09% reported in 2018Q1 SEC filing. Bvf Inc sold 386,100 shares as Chemocentryx Inc (CCXI)’s stock rose 32.26%. The Bvf Inc holds 7.20 million shares with $97.94 million value, down from 7.59M last quarter. Chemocentryx Inc now has $543.11M valuation. The stock decreased 1.43% or $0.16 during the last trading session, reaching $11.05. About 19,928 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 83.50% since August 3, 2017 and is uptrending. It has outperformed by 70.93% the S&P500. Some Historical CCXI News: 20/04/2018 – DJ Chemocentryx Inc, Inst Holders, 1Q 2018 (CCXI); 09/03/2018 – ChemoCentryx 4Q Rev $56.3M; 09/05/2018 – ChemoCentryx 1Q Loss/Shr 19c; 31/03/2018 – ChemoCentryx Conference Set By H.C. Wainwright for Apr. 8-10; 09/03/2018 – ChemoCentryx Intends to Initiate Clinical Development of Avacopan in Hidradenitis Suppurativa by Yr-En; 23/05/2018 – ChemoCentryx Announces Two Upcoming Presentations at the 55th ERA-EDTA Congress; 09/03/2018 ChemoCentryx 4Q EPS 80c; 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in the Treatment of Focal Segmental Glomerulosclerosis (FSGS); 09/03/2018 – ChemoCentryx Expects to Utilize Between $65M-$75M Cash and Investments in FY18; 11/04/2018 – ChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical Meeting
Valeant Pharmaceuticals International Inc (VRX) investors sentiment increased to 1.06 in 2018 Q1. It’s up 0.09, from 0.97 in 2017Q4. The ratio has improved, as 126 investment professionals increased and opened new equity positions, while 119 sold and decreased equity positions in Valeant Pharmaceuticals International Inc. The investment professionals in our database now hold: 167.32 million shares, down from 169.66 million shares in 2017Q4. Also, the number of investment professionals holding Valeant Pharmaceuticals International Inc in top ten equity positions increased from 4 to 6 for an increase of 2. Sold All: 29 Reduced: 90 Increased: 74 New Position: 52.
Another recent and important ChemoCentryx, Inc. (NASDAQ:CCXI) news was published by Nasdaq.com which published an article titled: “ChemoCentryx to Hold Second Quarter 2018 Financial Results Conference Call on Thursday, August 9, 2018” on August 02, 2018.
Bvf Inc increased Corvus Pharmaceuticals Inc stake by 1.49M shares to 1.95M valued at $22.53 million in 2018Q1. It also upped Pieris Pharmaceuticals Inc stake by 968,987 shares and now owns 3.59M shares. Protagonist Therapeutics Inc was raised too.
Investors sentiment decreased to 1 in Q1 2018. Its down 0.30, from 1.3 in 2017Q4. It is negative, as 10 investors sold CCXI shares while 36 reduced holdings. 24 funds opened positions while 22 raised stakes. 24.22 million shares or 3.03% more from 23.51 million shares in 2017Q4 were reported. 22,960 are held by Piermont Management. Legal & General Grp Public Llc holds 0% or 4,583 shares in its portfolio. Clarivest Asset Management Limited Liability Corporation reported 0.02% stake. 324,112 were accumulated by Millennium Mgmt Lc. Bvf Il stated it has 9.93% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Spark Mngmt Limited Liability reported 62,600 shares or 0.05% of all its holdings. The Germany-based Deutsche Retail Bank Ag has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Keybank Natl Association Oh holds 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI) for 45,740 shares. Goldman Sachs Group Incorporated Incorporated invested in 0% or 202,336 shares. Alliancebernstein LP owns 40,100 shares. Proshare Ltd Liability Com reported 25,705 shares stake. 39,000 are owned by J Goldman L P. Acadian Asset Mngmt Lc holds 0.03% in ChemoCentryx, Inc. (NASDAQ:CCXI) or 521,864 shares. California Employees Retirement Sys has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI). Paw Capital Corp invested 1.23% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI).
Analysts await ChemoCentryx, Inc. (NASDAQ:CCXI) to report earnings on August, 14. They expect $-0.11 earnings per share, up 42.11% or $0.08 from last year’s $-0.19 per share. After $-0.19 actual earnings per share reported by ChemoCentryx, Inc. for the previous quarter, Wall Street now forecasts -42.11% EPS growth.
Among 4 analysts covering ChemoCentryx (NASDAQ:CCXI), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ChemoCentryx had 4 analyst reports since March 13, 2018 according to SRatingsIntel. JP Morgan maintained ChemoCentryx, Inc. (NASDAQ:CCXI) on Tuesday, March 13 with “Overweight” rating.
Since May 1, 2018, it had 0 buys, and 12 insider sales for $7.89 million activity. $2.36M worth of ChemoCentryx, Inc. (NASDAQ:CCXI) was sold by Schall Thomas J. on Tuesday, May 15. $35,217 worth of ChemoCentryx, Inc. (NASDAQ:CCXI) was sold by Cappel Markus J. on Monday, May 21. $1.34 million worth of ChemoCentryx, Inc. (NASDAQ:CCXI) was sold by KANAYA SUSAN M on Tuesday, June 26.
Valeant Pharmaceuticals International, Inc. operates as a pharmaceutical and medical device firm worldwide. The company has market cap of $8.17 billion. It operates in three divisions: Bausch + Lomb/International, Branded Rx, and U.S. It has a 3.43 P/E ratio. Diversified Products.
Chou Associates Management Inc. holds 11.07% of its portfolio in Valeant Pharmaceuticals International, Inc. for 1.65 million shares. Goldentree Asset Management Lp owns 2.34 million shares or 6.54% of their US portfolio. Moreover, Valueact Holdings L.P. has 2.87% invested in the company for 18.01 million shares. The Illinois-based Bruce & Co. Inc. has invested 2.84% in the stock. Academy Capital Management Inc Tx, a Texas-based fund reported 607,618 shares.
Since January 1, 0001, it had 5 buys, and 0 sales for $1.42 million activity.
The stock decreased 3.43% or $0.83 during the last trading session, reaching $23.4. About 6.57 million shares traded. Valeant Pharmaceuticals International, Inc. (VRX) has risen 73.89% since August 3, 2017 and is uptrending. It has outperformed by 61.32% the S&P500. Some Historical VRX News: 08/05/2018 – Valeant Will Become Bausch Health Companies Inc; 22/05/2018 – FORMER VALEANT PHARMACEUTICALS INTERNATIONAL, PHILIDOR EXECUTIVES FOUND GUILTY OF DEFRAUDING VALEANT -NEW YORK COURT PROCEEDING; 22/05/2018 – Eli Lilly: Taltz Receives First FDA Approval for Label Update to Include Data for Psoriasis Involving Genital Area; 02/05/2018 – Valeant Pharmaceuticals: FDA Approves Bausch + Lomb ULTRA Contact Lenses for Extended Wear; 14/03/2018 – VALEANT GETS HEALTH CANADA APPROVAL OF SILIQ™ (BRODALUMAB) FOR; 12/04/2018 – newsbox.ch/ Cosmo Pharmaceuticals announces unfavourable award of Arbitral Tribunal in respect of request to terminate Uceris License Agreement with Valeant; 08/05/2018 – VALEANT – COMPANY’S NAME WILL CHANGE TO BAUSCH HEALTH COMPANIES INC. IN JULY 2018; 11/05/2018 – Progenics And Fellow Plaintiffs Valeant, Salix and Wyeth Reach Patent Settlement With Par Pharmaceutical; 21/03/2018 – Valeant: CEO Papa’s 2016 Total Pay Was $62.7 Million; 15/05/2018 – Valeant to Participate at the 2018 Barclays High Yield Bond and Syndicated Loan Conference
More recent Valeant Pharmaceuticals International, Inc. (NYSE:VRX) news were published by: Streetinsider.com which released: “The FDA approved a generic version of Valeant Pharma’s (VRX) Uceris” on July 05, 2018. Also Benzinga.com published the news titled: “Attention Biotech Investors: Mark Your Calendar For These August PDUFA Dates” on August 01, 2018. Seekingalpha.com‘s news article titled: “Insurers making headway on corralling drug costs with copay accumulators” with publication date: July 05, 2018 was also an interesting one.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.